Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M. Moreira A, et al. Among authors: le tourneau c. Eur J Cancer. 2019 Nov;121:202-209. doi: 10.1016/j.ejca.2019.09.001. Epub 2019 Oct 5. Eur J Cancer. 2019. PMID: 31593830
[Dose finding methods for targeted agents: new perspectives].
Paoletti X, Postel-Vinay S, Servois V, Doussau A, Ollivier L, Le Tourneau C. Paoletti X, et al. Among authors: le tourneau c. Bull Cancer. 2010 Dec;97(12):1485-95. doi: 10.1684/bdc.2010.1232. Bull Cancer. 2010. PMID: 21220226 Review. French.
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.
Bellera CA, Pulido M, Gourgou S, Collette L, Doussau A, Kramar A, Dabakuyo TS, Ouali M, Auperin A, Filleron T, Fortpied C, Le Tourneau C, Paoletti X, Mauer M, Mathoulin-Pélissier S, Bonnetain F. Bellera CA, et al. Among authors: le tourneau c. Eur J Cancer. 2013 Mar;49(4):769-81. doi: 10.1016/j.ejca.2012.09.035. Epub 2012 Nov 2. Eur J Cancer. 2013. PMID: 23122780
Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial.
Le Tourneau C, Kamal M, Trédan O, Delord JP, Campone M, Goncalves A, Isambert N, Conroy T, Gentien D, Vincent-Salomon A, Pouliquen AL, Servant N, Stern MH, Le Corroller AG, Armanet S, Rio Frio T, Paoletti X. Le Tourneau C, et al. Among authors: le corroller ag. Target Oncol. 2012 Dec;7(4):253-65. doi: 10.1007/s11523-012-0237-6. Epub 2012 Nov 17. Target Oncol. 2012. PMID: 23161020 Review.
280 results